{"product_id":"daily-aspirin-for-heart-attack-and-stroke-prevention-understanding-the-new-uspstf-guidance","title":"Daily Aspirin for Heart Attack and Stroke Prevention: Understanding the New USPSTF Guidance","description":"\u003cp\u003eThis article explains why the US Preventive Services Task Force (USPSTF) has updated its guidance on daily aspirin for heart attack and stroke prevention. The key takeaway: aspirin is no longer recommended for everyone — the new guidance calls for individual decision-making for adults aged 40–59 at increased heart risk and discourages aspirin for adults aged 60 and older who have not already had a heart attack or stroke.\u003c\/p\u003e\n\n\u003ch1\u003eDaily Aspirin for Heart Attack and Stroke Prevention: Understanding the New USPSTF Guidance\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#early\"\u003eThe Early Promise of Aspirin: What Initial Studies Found\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#usptf-2016\"\u003eThe 2016 USPSTF Recommendations: Aspirin's Earlier Role\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#trials-2018\"\u003eThe 2018 Landmark Trials: New Evidence Changes the Picture\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#trial-tips3\"\u003eThe TIPS-3 Trial (2020): A Polypill Plus Aspirin Approach\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#acc-aha-2019\"\u003eThe 2019 ACC\/AHA Guidelines: A Shift Toward Caution\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#usptf-2022\"\u003eThe 2021–2022 USPSTF Recommendation: The New Guidance\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Guidance Can't Tell Us\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations: Actionable Advice for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eUSPSTF now discourages starting aspirin for primary prevention in adults aged 60 or older.\u003c\/li\u003e\n\u003cli\u003eFor adults 40–59 at increased heart risk, aspirin decisions should be individualized based on bleeding risk.\u003c\/li\u003e\n\u003cli\u003eAspirin reduces cardiovascular events but increases major bleeding, so the net benefit varies by person.\u003c\/li\u003e\n\u003cli\u003eIn the ASPREE trial, healthy older adults taking aspirin had higher overall and cancer-related death rates.\u003c\/li\u003e\n\u003cli\u003eAspirin remains recommended for secondary prevention after a heart attack, stroke, or stent placement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\u003cp\u003eEvery day, millions of people take a low-dose aspirin hoping to prevent a first heart attack or stroke. This practice — known as \u003cstrong\u003eprimary prevention\u003c\/strong\u003e — refers to using a medication to prevent a first cardiovascular event in people who have no history of heart disease. Aspirin works by making blood platelets less sticky, reducing the chance a clot will form and block a blood vessel.\u003c\/p\u003e\n\u003cp\u003eBut aspirin comes with a well-known risk: it can cause bleeding, particularly in the stomach and intestines. So the central question has always been whether the benefit of preventing heart attacks and strokes outweighs the risk of bleeding. According to an editorial by Lloyd-Jones DM, published in \u003cem\u003eJAMA Cardiology\u003c\/em\u003e on April 26, 2022, and summarized by the American College of Cardiology, the answer is not a simple \"yes\" for everyone.\u003c\/p\u003e\n\u003cp\u003eThe editorial's central message is clear: aspirin therapy is not a one-size-fits-all treatment. It may offer benefit for some patients, while for others the risk–benefit ratio may not be favorable.\u003c\/p\u003e\n\n\u003ch2 id=\"early\"\u003eThe Early Promise of Aspirin: What Initial Studies Found\u003c\/h2\u003e\n\u003cp\u003eFor decades, aspirin was viewed as a powerful and inexpensive tool for heart disease prevention. Some of the most influential early studies seemed to support this view.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003ePhysicians' Health Study\u003c\/strong\u003e, one of the first major randomized trials, showed that aspirin use in primary prevention reduced the risk of \u003cstrong\u003emyocardial infarction\u003c\/strong\u003e (heart attack) among large populations of healthy male physicians. This finding helped establish the idea that aspirin could benefit many people.\u003c\/p\u003e\n\u003cp\u003eHowever, subsequent research complicated the picture. The \u003cstrong\u003eWomen's Health Study\u003c\/strong\u003e, another landmark trial, found \u003cstrong\u003eno reduction in major cardiovascular disease (CVD)\u003c\/strong\u003e with primary prevention aspirin use among women. Interestingly, the study did show a \u003cstrong\u003ereduction in stroke risk\u003c\/strong\u003e in the aspirin group. Taken together, these early trials suggested that the effects of aspirin might differ by sex and by the type of cardiovascular event, and that any benefits needed to be weighed carefully.\u003c\/p\u003e\n\u003cp\u003eOne important finding from those early trials has never changed: aspirin consistently produced \u003cstrong\u003esmall absolute increases in major bleeding risk\u003c\/strong\u003e. In absolute terms, the increases were small, but they represented real harm for some people.\u003c\/p\u003e\n\n\u003ch2 id=\"usptf-2016\"\u003eThe 2016 USPSTF Recommendations: Aspirin's Earlier Role\u003c\/h2\u003e\n\u003cp\u003eBased on the evidence available at the time, the USPSTF issued recommendations in 2016 that were more favorable toward aspirin:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients aged 50–59 years\u003c\/strong\u003e at elevated cardiovascular risk who were not at risk for bleeding were recommended to start low-dose aspirin (a \u003cstrong\u003eGrade B recommendation\u003c\/strong\u003e, meaning the USPSTF recommends the service with moderate-to-high certainty of net benefit).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients aged 60–69 years\u003c\/strong\u003e were offered a more individualized recommendation, with the decision left to the clinician and patient, again weighing cardiovascular risk against bleeding risk.\u003c\/li\u003e\n  \u003cli\u003eFor patients younger than 50 or older than 69 years, the USPSTF concluded there was \u003cstrong\u003einsufficient evidence\u003c\/strong\u003e to make a recommendation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAt the time, this guidance seemed reasonable. But the landscape of cardiovascular prevention was about to change dramatically.\n\n\u003c\/p\u003e\u003ch2 id=\"trials-2018\"\u003eThe 2018 Landmark Trials: New Evidence Changes the Picture\u003c\/h2\u003e\n\u003cp\u003eOver the past 30 years, large cardiovascular preventive efforts have greatly impacted public health. These include increasing use of \u003cstrong\u003estatin medications\u003c\/strong\u003e to lower cholesterol and \u003cstrong\u003eantihypertensive medications\u003c\/strong\u003e to control blood pressure, along with reductions in tobacco use. This means the \"baseline\" risk of cardiovascular events in modern populations is lower than in the older aspirin trials — leaving less room for aspirin to demonstrate additional benefit.\u003c\/p\u003e\n\u003cp\u003eIn 2018, three key trials of primary prevention with aspirin were published. Together, they reshaped the scientific debate.\u003c\/p\u003e\n\n\u003ch3\u003eASPREE Trial: Risks in Healthy Older Adults\u003c\/h3\u003e\n\u003cp\u003eThe \u003cstrong\u003eASPREE trial\u003c\/strong\u003e enrolled healthy older patients aged 65 years and older. Participants received either low-dose daily aspirin or placebo. The results were striking and concerning:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMortality (death from any cause):\u003c\/strong\u003e 5.9% in the aspirin group versus 5.2% in the placebo group at a median follow-up of 4.7 years — meaning aspirin was associated with an \u003cstrong\u003eincreased risk of death\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCancer mortality:\u003c\/strong\u003e 3.1% with aspirin versus 2.3% with placebo, again favoring placebo.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMajor bleeding:\u003c\/strong\u003e occurred at similar rates in both groups (0.3% in both groups).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis was a sobering finding: in healthy older adults, daily aspirin did not protect against death and was associated with \u003cstrong\u003ehigher overall and cancer-related mortality\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eASCEND Trial: Mixed Results in Diabetes Patients\u003c\/h3\u003e\n\u003cp\u003eThe \u003cstrong\u003eASCEND trial\u003c\/strong\u003e focused on patients with \u003cstrong\u003ediabetes\u003c\/strong\u003e, a group already at higher cardiovascular risk. Participants were randomized to daily low-dose aspirin or placebo and followed for a mean of 7.4 years:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCardiovascular events reduced:\u003c\/strong\u003e 8.5% in the aspirin group versus 9.6% in the placebo group — a meaningful reduction.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBut major bleeding increased:\u003c\/strong\u003e 4.1% with aspirin versus 3.2% with placebo.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe cardiovascular benefit was real, but it was largely offset by the increase in major bleeding. For patients with diabetes, the net benefit was therefore uncertain.\n\n\u003c\/p\u003e\u003ch3\u003eARRIVE Trial: No Significant Benefit, Doubled Bleeding\u003c\/h3\u003e\n\u003cp\u003eThe \u003cstrong\u003eARRIVE trial\u003c\/strong\u003e studied middle-aged and older adults at intermediate risk for \u003cstrong\u003eatherosclerotic cardiovascular disease (ASCVD)\u003c\/strong\u003e — a condition where arteries become narrowed and hardened by cholesterol plaque — but who did not have diabetes. Key results at a median follow-up of 5 years:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCardiovascular events:\u003c\/strong\u003e 4.29% in the aspirin group versus 4.48% in the placebo group — a \u003cstrong\u003enonsignificant reduction\u003c\/strong\u003e, meaning the difference could have been due to chance.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGastrointestinal bleeding nearly doubled:\u003c\/strong\u003e 0.97% with aspirin versus 0.46% with placebo.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn the ARRIVE trial, aspirin failed to provide a statistically meaningful benefit while notably increasing bleeding risk.\u003c\/p\u003e\n\n\u003ch2 id=\"trial-tips3\"\u003eThe TIPS-3 Trial (2020): A Polypill Plus Aspirin Approach\u003c\/h2\u003e\n\u003cp\u003eOne more trial, published after the 2018 trio, added an important twist. The \u003cstrong\u003eTIPS-3 trial\u003c\/strong\u003e (2020) enrolled patients at elevated risk for ASCVD who had \u003cstrong\u003elow baseline use\u003c\/strong\u003e of statin and blood pressure medications. Participants were randomized to receive aspirin or placebo \u003cstrong\u003ein addition to a \"polypill\"\u003c\/strong\u003e — a single combination pill containing a statin and antihypertensive medications.\u003c\/p\u003e\n\u003cp\u003eIn this setting, aspirin showed a \u003cstrong\u003esignificant reduction in cardiovascular events\u003c\/strong\u003e: 4.1% in the aspirin group versus 5.8% in the placebo group over a mean follow-up of 4.6 years.\u003c\/p\u003e\n\u003cp\u003eThis finding is important because it suggests that aspirin's benefit may be more evident in populations that have \u003cstrong\u003eless access to other preventive treatments\u003c\/strong\u003e. In the 2018 trials, rates of statin and antihypertensive use were already quite high, and tobacco use was relatively low. As the editorial notes, there may be \u003cstrong\u003eless opportunity for primary prevention aspirin to demonstrate benefit\u003c\/strong\u003e when other risk factors are already well controlled.\u003c\/p\u003e\n\n\u003ch2 id=\"acc-aha-2019\"\u003eThe 2019 ACC\/AHA Guidelines: A Shift Toward Caution\u003c\/h2\u003e\n\u003cp\u003eIn 2019, the American College of Cardiology (ACC), American Heart Association (AHA), and multispecialty organizations released updated primary prevention guidelines that reflected the mounting evidence:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAspirin was classified as \u003cstrong\u003eClass III (harm)\u003c\/strong\u003e for primary prevention in patients aged \u003cstrong\u003e70 years and older\u003c\/strong\u003e — meaning the potential harms clearly outweigh any benefits, and the medication \u003cstrong\u003eshould not be used\u003c\/strong\u003e in this group.\u003c\/li\u003e\n  \u003cli\u003eFor patients aged \u003cstrong\u003e40–70 years\u003c\/strong\u003e, the recommendation strength was reduced to \u003cstrong\u003eClass IIb\u003c\/strong\u003e, a \"weak\" recommendation indicating that the usefulness or effectiveness of aspirin is less well established. The guideline emphasized \u003cstrong\u003eindividual decision-making\u003c\/strong\u003e, weighing each patient's specific cardiovascular risk, bleeding risk, and preferences.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis represented a major shift. Aspirin was no longer a \"just in case\" medication for older adults; it was now seen as a potential source of harm in that population.\u003c\/p\u003e\n\n\u003ch2 id=\"usptf-2022\"\u003eThe 2021–2022 USPSTF Recommendation: The New Guidance\u003c\/h2\u003e\n\u003cp\u003eFollowing these developments, the USPSTF issued its updated recommendation for 2021–2022, further narrowing the role of aspirin in primary prevention:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients aged 40–59 years\u003c\/strong\u003e at increased risk of cardiovascular disease (typically a 10% or higher 10-year risk) should make an \u003cstrong\u003eindividualized decision\u003c\/strong\u003e with their clinician about starting aspirin. This applies only to patients who are not at increased risk for bleeding and who have a life expectancy of at least 10 years.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients aged 60 years and older:\u003c\/strong\u003e the USPSTF now \u003cstrong\u003ediscourages starting aspirin\u003c\/strong\u003e for primary prevention, because the risk of bleeding outweighs the potential cardiovascular benefit.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe difference from the 2016 guidance is significant. The age cutoff for regular use was lowered, and the recommendation for ages 60 and older flipped from \"individualized\" to \"discouraged.\" The message to patients is simple: if you haven't had a heart attack or stroke and you're over 60, daily aspirin is likely doing more harm than good.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\u003cp\u003eIf you or a loved one is currently taking daily aspirin for prevention, you may be wondering what to do. The first and most important point: \u003cstrong\u003edo not stop any medication without speaking to your doctor first\u003c\/strong\u003e. Some people take aspirin because they have already had a heart attack, stroke, or a stent placed — this is \u003cstrong\u003esecondary prevention\u003c\/strong\u003e, which is completely different.\u003c\/p\u003e\n\u003cp\u003eThe new USPSTF guidance applies only to \u003cstrong\u003eprimary prevention\u003c\/strong\u003e — that is, people who have never experienced a cardiovascular event. For those individuals, the takeaway is:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe decision to start aspirin should be made \u003cstrong\u003etogether with your healthcare provider\u003c\/strong\u003e, considering your age, your calculated cardiovascular risk, your bleeding risk, your other medications, and your personal preferences.\u003c\/li\u003e\n  \u003cli\u003eFor most people over 60, aspirin is likely to cause more harm than benefit in terms of primary prevention.\u003c\/li\u003e\n  \u003cli\u003eFor people 40–59 at increased risk, aspirin may be helpful for some but not others — an individual risk discussion is essential.\u003c\/li\u003e\n  \u003cli\u003eIf you have diabetes, the ASCEND trial shows aspirin can reduce heart attack and stroke risk, but this comes with an increased bleeding risk. This trade-off should be discussed explicitly with your doctor.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIt's also important to remember that aspirin is only one tool in the prevention toolkit. The broader impact on public health over the past 30 years has come primarily from \u003cstrong\u003estatins, blood pressure medications, and smoking cessation\u003c\/strong\u003e. These interventions address the root causes of cardiovascular disease, whereas aspirin only addresses clot formation.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Guidance Can't Tell Us\u003c\/h2\u003e\n\u003cp\u003eWhile the new USPSTF recommendation is based on the strongest evidence to date, important uncertainties remain:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe three major 2018 trials (ASPREE, ASCEND, ARRIVE) were each designed differently, with different patient populations, aspirin doses, and follow-up durations. Comparing them directly requires interpretation.\u003c\/li\u003e\n  \u003cli\u003eThe ASPREE trial's surprising finding of increased cancer mortality with aspirin was not anticipated and has not been fully explained. It remains unclear whether this reflects a true effect or a chance finding.\u003c\/li\u003e\n  \u003cli\u003eThe TIPS-3 trial suggests aspirin may be more beneficial in populations with limited access to statins and blood pressure medications. This means the \"right\" answer may depend on where you live and what other treatments are available to you.\u003c\/li\u003e\n  \u003cli\u003eThe USPSTF guidance applies to typical adults and may not address specific high-risk groups, such as people with chronic kidney disease, familial hypercholesterolemia, or other conditions that elevate cardiovascular risk in ways not fully captured by standard risk calculators.\u003c\/li\u003e\n  \u003cli\u003eGastrointestinal bleeding was the most commonly measured harm, but aspirin also raises the risk of hemorrhagic stroke (bleeding in the brain) and other serious bleeding events. These outcomes were less consistently reported across trials.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eNo guideline can replace a thoughtful conversation between a patient and clinician. Your individual bleeding risk depends on factors such as age, kidney function, history of stomach ulcers, use of blood thinners or anti-inflammatory pain relievers (NSAIDs), and blood pressure control. These details matter enormously.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations: Actionable Advice for Patients\u003c\/h2\u003e\n\u003cp\u003eIf you are considering starting — or continuing — daily aspirin for primary prevention, here are concrete steps you can take:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your numbers.\u003c\/strong\u003e Ask your doctor to calculate your 10-year ASCVD risk, which includes your age, sex, race, blood pressure, cholesterol levels, smoking status, and diabetes status. This is the single most important starting point.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about your bleeding risk.\u003c\/strong\u003e Tell your doctor if you have a history of stomach ulcers, gastrointestinal bleeding, kidney disease, or bleeding disorders. Mention any medications that increase bleeding risk, including blood thinners, NSAIDs, steroids, and some herbal supplements.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss the evidence with your doctor.\u003c\/strong\u003e Share your age and ask specifically whether the new USPSTF guidance applies to you. If you are 60 or older, expect that the recommendation may lean against starting aspirin for primary prevention.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't stop aspirin suddenly.\u003c\/strong\u003e If you are already taking aspirin and your doctor agrees it's no longer needed, discuss a safe plan for stopping. For secondary prevention (after a heart attack, stroke, or stent), aspirin is still recommended and should generally be continued indefinitely unless there is a strong reason to stop.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFocus on proven prevention strategies.\u003c\/strong\u003e Aspirin should never be a substitute for a heart-healthy lifestyle. Work on blood pressure control, cholesterol management with statins when indicated, smoking cessation, a balanced diet, and regular physical activity. These strategies have the largest impact on cardiovascular health.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eIn summary, the new guidance reflects a maturing understanding: aspirin remains a powerful and life-saving medication for people who have already had cardiovascular events, but for primary prevention, its role is narrower, more selective, and carefully weighed against the harms.\u003c\/p\u003e\n\u003cp\u003eAs the editorial's author, Geoffrey D. Barnes, MD, MSc, FACC, emphasizes, aspirin is not a one-size-fits-all therapy. The next time you see your doctor, make sure your aspirin decision is based on your personal risk profile — not on habits or advice from decades past.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eIf I am over 60 and have never had a heart attack or stroke, should I stop taking daily aspirin?\u003c\/h3\u003e\n\u003cp\u003eThe updated USPSTF guidance discourages starting aspirin for primary prevention in adults aged 60 and older because the risk of bleeding outweighs the potential cardiovascular benefit. If you are already taking aspirin, do not stop suddenly. Talk with your doctor first to make a safe decision based on your personal health situation.\u003c\/p\u003e\n\u003ch3\u003eWhat exactly is the difference between primary and secondary prevention of heart attack and stroke?\u003c\/h3\u003e\n\u003cp\u003ePrimary prevention means taking a medication to prevent a first heart attack or stroke in someone who has never had one. Secondary prevention is for people who have already had a heart attack, stroke, or stent placement. The new USPSTF guidance applies only to primary prevention. Aspirin remains recommended for secondary prevention.\u003c\/p\u003e\n\u003ch3\u003eI already had a heart attack. Does the new guidance mean I should stop taking aspirin?\u003c\/h3\u003e\n\u003cp\u003eNo. The new USPSTF guidance applies only to primary prevention — people who have never had a cardiovascular event. If you have already had a heart attack, stroke, or stent, aspirin is considered secondary prevention. In that setting, aspirin is still recommended and should generally be continued indefinitely, but always discuss any changes with your doctor.\u003c\/p\u003e\n\u003ch3\u003eWhy did the advice about daily aspirin change so much?\u003c\/h3\u003e\n\u003cp\u003eNew evidence from 2018 trials, including ASPREE, ASCEND, and ARRIVE, showed that aspirin's benefit in primary prevention is smaller than previously thought. Meanwhile, the risk of serious bleeding remains. Modern treatments like statins and blood pressure medications have also lowered baseline heart risk, leaving less room for aspirin to help. The guidance now discourages aspirin for adults over 60.\u003c\/p\u003e\n\u003ch3\u003eWhat are the main harms of taking daily aspirin?\u003c\/h3\u003e\n\u003cp\u003eAspirin can cause bleeding, especially in the stomach and intestines. It also raises the risk of hemorrhagic stroke. In the ARRIVE trial, gastrointestinal bleeding nearly doubled with aspirin. The ASPREE trial found increased death and cancer mortality in healthy older adults taking aspirin. These risks are why aspirin is no longer recommended for everyone.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my doctor before starting or continuing daily aspirin?\u003c\/h3\u003e\n\u003cp\u003eAsk your doctor to calculate your 10-year ASCVD risk score, which includes age, blood pressure, cholesterol, smoking, and diabetes status. Ask about your personal bleeding risk, including history of ulcers, kidney disease, or use of blood thinners and NSAIDs. Also ask how the new USPSTF guidance applies to your age and whether you need aspirin at all.\u003c\/p\u003e\n\u003ch3\u003eWhen should I seek a second opinion about starting or stopping daily aspirin for primary prevention of heart attack and stroke?\u003c\/h3\u003e\n\u003cp\u003eDaily aspirin for primary prevention is no longer recommended for everyone. For adults 60 and older who have not had a heart attack or stroke, current guidance discourages starting it because bleeding risk outweighs possible benefit. For adults 40–59 at increased cardiovascular risk, the decision is individualized, considering age, bleeding risk, other medications, and preferences. If you are unsure whether aspirin is right for you, a second opinion can help you weigh these factors against the latest evidence. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e USPSTF Report on Aspirin for Primary Prevention - American College of Cardiology\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEditorial Author:\u003c\/strong\u003e Lloyd-Jones DM\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal Citation:\u003c\/strong\u003e USPSTF Report on Aspirin for Primary Prevention. \u003cem\u003eJAMA Cardiol\u003c\/em\u003e 2022;Apr 26:[Epub ahead of print].\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSummary Author:\u003c\/strong\u003e Geoffrey D. Barnes, MD, MSc, FACC\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication Date:\u003c\/strong\u003e April 26, 2022\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eClinical Topics Covered:\u003c\/strong\u003e Dyslipidemia, Geriatric Cardiology, Prevention, Nonstatins, Novel Agents, Statins\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKeywords:\u003c\/strong\u003e Antihypertensive Agents, Aspirin, Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Gastrointestinal Hemorrhage, Geriatrics, Heart Disease Risk Factors, Hemorrhage, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Myocardial Infarction, Neoplasms, Primary Prevention, Public Health, Risk Assessment, Risk Factors, Stroke, Tobacco Use\u003c\/p\u003e\n\u003cp\u003e© 2023 American College of Cardiology Foundation. All rights reserved.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research and professionally authored summaries. It is for educational purposes only and is not a substitute for individualized medical advice. Always consult your physician about your specific health situation.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47576660312220,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/es\/products\/daily-aspirin-for-heart-attack-and-stroke-prevention-understanding-the-new-uspstf-guidance","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}